Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VICTOR: oral AK0529 in hospitalized infants and toddlers with RSV
MOH_2017-08-10_000395Phase 2Not yet recruiting
- Sponsor
- Ark Biosciences
- Start
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ziresovir in respiratory syncytial virus disease (RSV) (4 cohorts), sponsored by Ark Biosciences. Primary endpoint: Safety and tolerability of single and multiple oral doses of AK0529. Planned start May 2017; status: not yet recruiting.
02
Drugs
ziresovir
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on MOH_2017-08-10_000395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-08-10_000395.